Evidence map›Paper›PMID 41209711›Full record

ArticleMaterials today. Bio2025

Nanodelivery of panobinostat induces cell cycle arrest and apoptosis to suppress hepatocellular carcinoma growth in mice.

Yutong Li, Dong Li, Junjun Chen, Yuqiong Gao, Xingze Zou, Huan Li, Zhuo Yu, Yifang Zou, Jianfeng Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Water-Soluble Polysaccharide fromFoods (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yutong LiSchool of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.
Dong LiDepartment of Pharmacy, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130021, China.
Junjun ChenDepartment of Pharmacy, The Second Hospital of Jilin University, Changchun, 130041, China.
Yuqiong GaoSchool of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.
Xingze ZouSchool of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.
Huan LiSchool of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.
Zhuo YuDepartment of Hepatopathy, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yifang ZouSchool of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.
Jianfeng GuoSchool of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC), the predominant subtype of primary liver cancer, remains as a globally lethal malignancy with limited therapeutic options. Despite therapeutic efficacy of small-molecule inhibitors, the majority of HCC patients are still incurable due to suboptimal response rate and serious systemic toxicity. Panobinostat (PANO), a potent histone deacetylase (HDAC) small-molecule inhibitor, has established clinical efficacy in hematological malignancies. However, clinical application of PANO in solid tumors (e.g., HCC) is significantly hindered by

Indexed as

CopolymerEpigenetic modulationLiver cancerNanoformulationTargeted therapy

Identifiers

PMID41209711
PMCPMC12590151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.